Diabetic Peripheral Neuropathic Pain (DPNP) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Diabetic Peripheral Neuropathic Pain (DPNP) Market Outlook

Thelansis’s “Diabetic Peripheral Neuropathic Pain (DPNP) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Diabetic Peripheral Neuropathic Pain treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Diabetic Peripheral Neuropathic Pain (DPNP) Overview

Peripheral neuropathic pain (PNP) is a distressing and enduring chronic pain syndrome that can manifest following damage or disease affecting the peripheral somatosensory nervous system or due to drug triggers. PNP causes vary and can be categorized based on whether nerve damage arises from systemic factors like diseases, toxins, or medications or localized secondary effects like trauma, surgery, or cancer. The signs and symptoms of PNP can fluctuate as the disease progresses and can be influenced by the patient's emotional state and anxiety levels. Neuralgias typically exhibit characteristic episodic paroxysms, whereas other neuropathic pains may occur as isolated episodes or as increasing intensity attacks on top of a continuous pain background. Peripheral neuropathy encompasses various types, with risk factors contingent upon the underlying condition or the affected nerves. PNP can either be congenital or develop due to injury or illness. The most prevalent form of peripheral neuropathy is associated with diabetes, affecting approximately 60–70% of diabetic patients. The numerous causes of peripheral neuropathy can be categorized as hereditary, infectious, immunologic, metabolic, mechanical, cancer-related, toxic, or idiopathic. Neuropathic pain syndromes represent chronic pain disorders resulting from nervous system lesions or diseases that typically transmit pain signals. These conditions encompass various situations, including health conditions, specific medications, or trauma. However, in some instances, the cause remains unidentified, termed idiopathic neuropathy. The Neuropathic Pain Special Interest Group (NeuPSIG) of the International Association for the Study of Pain (IASP) recommends tricyclic antidepressants, gabapentin or pregabalin, and the SNRIs venlafaxine or duloxetine as first-line treatments for neuropathic pain. Second-line options encompass tramadol, topical lidocaine, or high-concentration capsaicin. Strong opioids (Morphine and Oxycodone) and botulinum toxin-A (BTX-A) are included as third-line treatments for peripheral neuropathic pain. Cannabinoids and valproate receive weak recommendations against their use in neuropathic pain. Chronic neuropathic pain is more prevalent in women and individuals over 50, typically affecting areas like the lower back and limbs and the neck and upper limbs.

• The prevalence of peripheral neuropathy among adults with diabetes varies significantly, estimated to range from 6% to 51%. This wide range is influenced by factors such as age, duration of diabetes, glucose control, and whether the diabetes is type 1 or type 2.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: